<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03299062</url>
  </required_header>
  <id_info>
    <org_study_id>206829</org_study_id>
    <nct_id>NCT03299062</nct_id>
  </id_info>
  <brief_title>Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders</brief_title>
  <official_title>Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Degenerative dementias including Alzheimer's Disease (AD), Parkinson's Disease with Dementia&#xD;
      (PDD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementias (FTLD), Corticobasal&#xD;
      Degeneration (CBD) and Progressive Supranuclear Palsy (PSP) constitute a significant, and&#xD;
      growing burden with an estimated cost to the US healthcare system for 2016 of $236 Billion&#xD;
      (1). Definitive diagnosis of these dementias is based on pathological criterion upon autopsy,&#xD;
      which presents a significant challenge to establish diagnosis in living patients. Although&#xD;
      clinical diagnostic criteria have been developed for several of these disorders, including&#xD;
      for Alzheimer's Disease (AD) by the National Institute of Neurological and Communicative&#xD;
      Disorders and Stroke and Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA)&#xD;
      , Parkinson's Disease (PD) by the United Kingdom Parkinson Disease Brain Bank Diagnostic&#xD;
      Criteria (UKPDBB) diagnostic criteria for Parkinson Disease(4) and others, the currently&#xD;
      available tests, including the use of imaging markers and Cerebrospinal Fluid (CSF)&#xD;
      biological markers do not provide a definite diagnosis since this requires the observation of&#xD;
      characteristic neuropathological changes in specific regions of the brain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Actual">December 21, 2021</completion_date>
  <primary_completion_date type="Actual">December 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alpha-synuclein levels from nasal swabs</measure>
    <time_frame>Up to 4 weeks after swab is completed</time_frame>
    <description>Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, Amyloid-beta (A-beta) and Phospho-tau (p-tau) staining.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Neurodegenerative Diseases</condition>
  <arm_group>
    <arm_group_label>Parkinson's Disease with Voice Dysfunction Patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• Twenty people with Parkinson's Disease requiring evaluation of voice dysfunction by an Ear, Nose, and Throat (ENT) doctor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Neurodegenerative Disorders with Voice Dysfunction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• Twenty people with other neurodegenerative disorders requiring evaluation of voice dysfunction by an ENT doctor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voice Dysfunction</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twenty people with voice tremor and/or presbylarynx, but no evidence of Parkinson's other neurodegenerative disease, requiring evaluation of voice dysfunction by an ENT doctor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cytology and Immunohistochemistry</intervention_name>
    <description>Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.</description>
    <arm_group_label>Other Neurodegenerative Disorders with Voice Dysfunction</arm_group_label>
    <arm_group_label>Parkinson's Disease with Voice Dysfunction Patients</arm_group_label>
    <arm_group_label>Voice Dysfunction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with idiopathic Parkinson's disease, progressive supranuclear palsy,&#xD;
             Alzheimer's disease or Mild Cognitive Impairment based on consensus criteria, or&#xD;
             suspicion of presbylarynx based on clinical evaluation.&#xD;
&#xD;
          -  Require evaluation of voice dysfunction by an ENT doctor given symptoms of impaired&#xD;
             voice volume or quality&#xD;
&#xD;
          -  Age ≥ 18 years-old to ≤ 90-years old.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Active nose bleeds, or abnormal anatomy of the nose that prevent safe nasal swabs, or&#xD;
             active oropharyngeal disease that prevents laryngoscopy or voice assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rohit Dhall, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>September 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>January 11, 2022</last_update_submitted>
  <last_update_submitted_qc>January 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 28, 2022</submitted>
    <returned>October 26, 2022</returned>
    <submitted>October 31, 2022</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

